Skip to main content

Power IgAN research with real-world data insights

  

At Quest Diagnostics, we’re committed to helping pharmaceutical and biotech companies bring innovative treatments to market. By harnessing our real-world data, we can help support every stage of the drug development journey—from early research and clinical trials to commercialization and post-market surveillance.

Gain powerful insights from labs, EHR and claims data to fuel IgAN research, clinical trials, and commercialization

Our IgAN data includes key biomarkers and combines data from labs, EHRs, and claims, delivering a comprehensive view of the patient journey. All data is securely tokenized—replacing personally identifiable information with unique tokens to ensure patient privacy and meet regulatory standards. This integrated data combination empowers more informed decisions and accelerates progress across IgAN research and commercialization, without compromising confidentiality.

Our IgAN data includes relevant clinical biomarkers essential for disease discovery, diagnosis, prognosis, therapy selection and monitoring– empower data-driven decision-making throughout the entire drug development lifecycle.

Power your IgAN research with real-world data from Quest

829

* indicates required

  

*Estimated volumes from March 2024 - April 2025

  

Transform data into decisions with expert-led analysis

At Quest, we don’t just deliver data, we deliver actionable insights. We offer expert support to help unlock the full potential of lab, EHR, and claims data to power patient journey mapping, safety studies, and predictive analytics. Whether you need additional support or lack internal resources, we bring the clinical and analytical expertise to turn real-world data into actionable insights that can help accelerate development and drive more impactful outcomes.

Accelerate IgAN trial enrollment with Quest

By leveraging our extensive clinical data, Quest can help identify eligible patients for an IgAN study and engage both patients and their physicians to drive awareness of the trial, enabling faster and more efficient enrollment.